Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.

Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y.

Int Immunopharmacol. 2005 Nov;5(12):1731-40.

PMID:
16102523
2.

Humanized antihuman IL-6 receptor antibody, tocilizumab.

Nishimoto N, Kishimoto T.

Handb Exp Pharmacol. 2008;(181):151-60. Review.

PMID:
18071945
3.

sIL-6R: more than an agonist?

Knüpfer H, Preiss R.

Immunol Cell Biol. 2008 Jan;86(1):87-91. Epub 2007 Aug 28. Review.

PMID:
17724457
4.

Interleukin-6 and its receptors: a highly regulated and dynamic system.

Wolf J, Rose-John S, Garbers C.

Cytokine. 2014 Nov;70(1):11-20. doi: 10.1016/j.cyto.2014.05.024. Epub 2014 Jun 28. Review.

PMID:
24986424
5.

Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.

Rose-John S, Scheller J, Elson G, Jones SA.

J Leukoc Biol. 2006 Aug;80(2):227-36. Epub 2006 May 17. Review.

PMID:
16707558
6.

The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.

Rose-John S.

Clin Pharmacol Ther. 2017 Oct;102(4):591-598. doi: 10.1002/cpt.782. Epub 2017 Jul 29. Review.

PMID:
28675418
7.

IL-6 transsignaling: the in vivo consequences.

Jones SA, Richards PJ, Scheller J, Rose-John S.

J Interferon Cytokine Res. 2005 May;25(5):241-53. Review.

PMID:
15871661
8.

Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.

Drucker C, Gewiese J, Malchow S, Scheller J, Rose-John S.

J Autoimmun. 2010 Feb;34(1):29-37. doi: 10.1016/j.jaut.2009.08.003. Epub 2009 Aug 29. Review.

PMID:
19717281
9.

IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.

Rose-John S.

Int J Biol Sci. 2012;8(9):1237-47. doi: 10.7150/ijbs.4989. Epub 2012 Oct 24. Review.

10.

IL-6/IL-6 receptor system and its role in physiological and pathological conditions.

Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M.

Clin Sci (Lond). 2012 Feb;122(4):143-59. doi: 10.1042/CS20110340. Review.

PMID:
22029668
11.

The IL-6/sIL-6R complex as a novel target for therapeutic approaches.

Rose-John S, Waetzig GH, Scheller J, Grötzinger J, Seegert D.

Expert Opin Ther Targets. 2007 May;11(5):613-24. Review.

PMID:
17465721
12.

Cytokines are a therapeutic target for the prevention of inflammation-induced cancers.

Rose-John S, Schooltink H.

Recent Results Cancer Res. 2007;174:57-66. Review.

PMID:
17302185
13.

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Jones SA, Scheller J, Rose-John S.

J Clin Invest. 2011 Sep;121(9):3375-83. doi: 10.1172/JCI57158. Epub 2011 Sep 1. Review.

14.

Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.

Cronstein BN.

Bull NYU Hosp Jt Dis. 2007;65 Suppl 1:S11-5. Review.

15.

Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.

Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M.

Clin Rev Allergy Immunol. 2005 Jun;28(3):231-8. Review.

PMID:
16129907
16.

Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation.

Lokau J, Agthe M, Garbers C.

Mediators Inflamm. 2016;2016:1785021. doi: 10.1155/2016/1785021. Epub 2016 Jul 14. Review.

17.

Interleukin-6 and its receptor: from bench to bedside.

Scheller J, Rose-John S.

Med Microbiol Immunol. 2006 Dec;195(4):173-83. Epub 2006 May 31. Review.

PMID:
16741736
18.

Interleukin-6 as a key player in systemic inflammation and joint destruction.

Fonseca JE, Santos MJ, Canhão H, Choy E.

Autoimmun Rev. 2009 Jun;8(7):538-42. doi: 10.1016/j.autrev.2009.01.012. Epub 2009 Feb 2. Review.

PMID:
19189867
19.

Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.

Nakahara H, Nishimoto N.

Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):373-81. Review.

PMID:
17214583
20.

Proteolytic control of Interleukin-11 and Interleukin-6 biology.

Lokau J, Agthe M, Flynn CM, Garbers C.

Biochim Biophys Acta. 2017 Nov;1864(11 Pt B):2105-2117. doi: 10.1016/j.bbamcr.2017.06.008. Epub 2017 Jun 16. Review.

PMID:
28630024

Supplemental Content

Support Center